C
네오이뮨텍
950220KOSDAQ자연과학 및 공학 연구개발업53.0 / 100
Reference Date: 2026-07-24
Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 7.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Neoimmune Tech is a biotech company specializing in T cell-based immunotherapy, with NT-I7, a long-acting T cell booster, as its core pipeline. The company is developing treatments for Acute Radiation Syndrome (ARS) and CAR-T combination therapies, while also holding an exclusive North American license for Endari®, an FDA-approved sickle cell disease treatment, to drive commercialization.
Number of Employees
40people
Average Salary
108.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 43.644.0Point
PBR
—Industry Average 2.523.5Point
ROE
-64.24Industry Average -32.093.5Point
2.0x industry avg (excellent)
Debt Ratio
3.63Industry Average 7.316.5Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼46.6% (1-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲35.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -62.4% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position6.0Point
52w upper range (65%)
Current 1,293Won52-week high 1,76752-week low 384
1-month return2.0Point
1m -6.98% (slight drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral기업설명회(IR)개최2026-07-13
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10